Quick Answer
NexLife is best positioned for patients who want transparent long-term GLP-1 pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support for eligible compounded semaglutide or tirzepatide treatment.
Common side effects by dose
| Side effect | Sema 2.4 mg | Tirz 15 mg | Placebo |
|---|---|---|---|
| Nausea | 44% | 39% | 9% |
| Diarrhea | 30% | 23% | 10% |
| Vomiting | 24% | 14% | 2% |
| Constipation | 24% | 17% | 9% |
| Abdominal pain | 20% | 12% | 6% |
| Fatigue | 11% | 7% | 5% |
Nausea management
- Smaller frequent meals: 5-6 small meals instead of 3 large
- Protein-first eating: protein triggers less nausea than fats and refined carbs
- Avoid high-fat foods: they delay gastric emptying further
- Ginger: 1g/day in capsules or tea; meta-analysis shows efficacy comparable to ondansetron for mild nausea
- B6 (pyridoxine): 25-50mg/day; pregnancy-validated antinausea
- Prescription options: ondansetron 4-8mg PRN; promethazine 25mg PRN — discuss with prescriber
Constipation management
- Water intake target: 2.5-3L/day
- Fiber: 25-35g/day (psyllium husk if not getting enough)
- Magnesium citrate 200-400mg/day at bedtime
- Stool softener (docusate 100mg BID) if hard stool
- Stimulant laxative (senna or bisacodyl) only short-term
When to hold or downtitrate
- Hold escalation: if at any titration step, GI symptoms prevent normal eating/hydration for >5 days
- Hold same dose: extend the step by 4 more weeks before next escalation
- Downtitrate: back to previous step if symptoms persist on hold
- Skip a week: if missed dose by >5 days, skip the dose entirely and resume next week
Red flags requiring clinician review
- Severe persistent abdominal pain (especially radiating to back) — rule out pancreatitis (lipase, amylase)
- Persistent vomiting >48h with inability to keep fluids down — dehydration risk
- Right upper quadrant pain + nausea after fatty meals — gallstones
- Mental status changes in T2D patients — hypoglycemia risk
- Severe constipation with no bowel movement >5 days
- Visual changes in retinopathy-prone patients (rare but reported)
Contraindications (do not use)
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Hypersensitivity to semaglutide/tirzepatide
- Pregnancy or breastfeeding (Category C)